Treatment of Attention-Deficit/Hyperactivity Disorder in Outpatients With a History of Disordered Eating Symptoms.

IF 0.8 4区 医学 Q4 CLINICAL NEUROLOGY
Clinical Neuropharmacology Pub Date : 2025-03-01 Epub Date: 2025-02-17 DOI:10.1097/WNF.0000000000000626
Robert P Wilfahrt, Abigail L Matthews
{"title":"Treatment of Attention-Deficit/Hyperactivity Disorder in Outpatients With a History of Disordered Eating Symptoms.","authors":"Robert P Wilfahrt, Abigail L Matthews","doi":"10.1097/WNF.0000000000000626","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of the study was to assess the characteristics and outcomes of adults with attention-deficit/hyperactivity disorder (ADHD) and a previous history of restrictive eating disorder symptoms.</p><p><strong>Method: </strong>We retrospectively reviewed the health records of patients with ADHD and a history of disordered eating who were treated at our institution with medications that have potential anorexiant properties from October 1, 2022, through March 31, 2024.</p><p><strong>Results: </strong>We initially identified 159 patients who were referred to an ADHD program at our institution during the study period. Of 72 patients who met criteria for an ADHD diagnosis, 18 had SCOFF questionnaire scores of 2 or higher, which suggests symptoms of a restrictive eating disorder. Of these 18 patients, 3 had a previous diagnosis of an eating disorder documented in their health records. Each patient was treated with medications chosen to manage their reported ADHD symptoms, regardless of eating disorder concerns. All patients had improvements in ADHD symptoms without reporting adverse effects on disordered eating behaviors. Body weight and body mass index values did not significantly change after treatment with atomoxetine, dextroamphetamine/amphetamine, or methylphenidate (all P ≥ 0.14).</p><p><strong>Conclusions: </strong>Our findings are consistent with those of previous reports and suggest that ADHD treatment, including treatment with stimulant medications, is safe and tolerable for patients with a history of restrictive eating disorder symptoms.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"39-42"},"PeriodicalIF":0.8000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WNF.0000000000000626","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/17 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The aim of the study was to assess the characteristics and outcomes of adults with attention-deficit/hyperactivity disorder (ADHD) and a previous history of restrictive eating disorder symptoms.

Method: We retrospectively reviewed the health records of patients with ADHD and a history of disordered eating who were treated at our institution with medications that have potential anorexiant properties from October 1, 2022, through March 31, 2024.

Results: We initially identified 159 patients who were referred to an ADHD program at our institution during the study period. Of 72 patients who met criteria for an ADHD diagnosis, 18 had SCOFF questionnaire scores of 2 or higher, which suggests symptoms of a restrictive eating disorder. Of these 18 patients, 3 had a previous diagnosis of an eating disorder documented in their health records. Each patient was treated with medications chosen to manage their reported ADHD symptoms, regardless of eating disorder concerns. All patients had improvements in ADHD symptoms without reporting adverse effects on disordered eating behaviors. Body weight and body mass index values did not significantly change after treatment with atomoxetine, dextroamphetamine/amphetamine, or methylphenidate (all P ≥ 0.14).

Conclusions: Our findings are consistent with those of previous reports and suggest that ADHD treatment, including treatment with stimulant medications, is safe and tolerable for patients with a history of restrictive eating disorder symptoms.

有进食障碍病史的门诊患者注意缺陷/多动障碍的治疗
目的:本研究的目的是评估患有注意力缺陷/多动障碍(ADHD)且既往有限制性饮食障碍症状史的成年人的特征和结果。方法:我们回顾性回顾了2022年10月1日至2024年3月31日期间在我们机构接受具有潜在厌食特性的药物治疗的ADHD和饮食失调病史患者的健康记录。结果:我们最初确定了159名患者,他们在研究期间被转介到我们机构的ADHD项目。在72名符合ADHD诊断标准的患者中,18名SCOFF问卷得分为2分或更高,这表明有限制性饮食失调的症状。在这18名患者中,有3人在健康记录中曾被诊断为饮食失调。每位患者都接受了药物治疗,以控制他们报告的多动症症状,而不考虑饮食失调的问题。所有患者的ADHD症状均有所改善,但未报告对饮食紊乱行为的不良影响。服用托莫西汀、右旋安非他明/安非他明或哌甲酯治疗后,体重和体重指数值无显著变化(P均≥0.14)。结论:我们的研究结果与之前的报告一致,表明ADHD治疗,包括兴奋剂药物治疗,对于有限制性饮食障碍症状史的患者是安全且可耐受的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Neuropharmacology
Clinical Neuropharmacology 医学-临床神经学
CiteScore
1.20
自引率
10.00%
发文量
63
审稿时长
6-12 weeks
期刊介绍: Clinical Neuropharmacology is a peer-reviewed journal devoted to the pharmacology of the nervous system in its broadest sense. Coverage ranges from such basic aspects as mechanisms of action, structure-activity relationships, and drug metabolism and pharmacokinetics, to practical clinical problems such as drug interactions, drug toxicity, and therapy for specific syndromes and symptoms. The journal publishes original articles and brief reports, invited and submitted reviews, and letters to the editor. A regular feature is the Patient Management Series: in-depth case presentations with clinical questions and answers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信